Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.83)
# 1,558
Out of 4,479 analysts
68
Total ratings
30.65%
Success rate
-9.15%
Average return
Main Sectors:
32 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCUL Ocular Therapeutix | Maintains: Overweight | $15 | $6.66 | +125.23% | 4 | Jun 14, 2024 | |
| BMEA Biomea Fusion | Maintains: Overweight | $45 → $10 | $4.42 | +126.24% | 4 | Jun 7, 2024 | |
| HALO Halozyme Therapeutics | Downgrades: Neutral | $48 → $51 | $52.02 | -1.96% | 4 | Jun 7, 2024 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $35 | $20.91 | +67.38% | 1 | Jun 5, 2024 | |
| CTMX CytomX Therapeutics | Upgrades: Overweight | $2.25 → $3.5 | $1.33 | +163.16% | 2 | May 28, 2024 | |
| CNTX Context Therapeutics | Initiates: Overweight | $4.5 | $1.81 | +148.62% | 1 | May 16, 2024 | |
| IBRX ImmunityBio | Maintains: Neutral | $5 → $6 | $6.27 | -4.31% | 3 | Apr 29, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Overweight | $26 → $30 | $5.86 | +411.95% | 2 | Apr 25, 2024 | |
| BOLD Boundless Bio | Initiates: Overweight | $20 | $4.19 | +377.33% | 1 | Apr 22, 2024 | |
| ACHL Achilles Therapeutics | Downgrades: Neutral | $8 → $2 | $0.80 | +149.38% | 3 | Apr 5, 2024 | |
| KROS Keros Therapeutics | Maintains: Overweight | $105 | $43.77 | +139.89% | 2 | Mar 27, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Overweight | $28 | $17.69 | +58.28% | 1 | Mar 27, 2024 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $40 | $13.58 | +194.55% | 4 | Mar 26, 2024 | |
| IMAB I-Mab | Maintains: Overweight | $15 → $10 | $1.62 | +517.28% | 4 | Mar 18, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $19 | $8.06 | +135.73% | 6 | Mar 14, 2024 | |
| RVMD Revolution Medicines | Initiates: Overweight | $43 | $38.81 | +10.80% | 1 | Mar 11, 2024 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $5 → $7 | $2.05 | +241.46% | 3 | Mar 1, 2024 | |
| SDGR Schrödinger | Maintains: Overweight | $60 → $50 | $18.76 | +166.52% | 2 | Feb 29, 2024 | |
| TNGX Tango Therapeutics | Initiates: Overweight | $18 | $9.00 | +100.00% | 1 | Feb 12, 2024 | |
| AADI Aadi Bioscience | Maintains: Overweight | $30 → $5 | $1.42 | +252.11% | 2 | Dec 15, 2023 | |
| RPTX Repare Therapeutics | Maintains: Overweight | $30 → $25 | $3.33 | +650.75% | 3 | Oct 16, 2023 | |
| TSBX Turnstone Biologics | Initiates: Overweight | $20 | $2.65 | +654.72% | 1 | Aug 15, 2023 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $100 | $68.64 | +45.69% | 2 | Jul 24, 2023 | |
| BDTX Black Diamond Therapeutics | Initiates: Overweight | $11 | $4.70 | +134.04% | 1 | Jul 14, 2023 | |
| EXEL Exelixis | Assumes: Overweight | $28 | $22.25 | +25.84% | 1 | May 10, 2023 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Overweight | $18 → $20 | $15.77 | +26.82% | 1 | Dec 20, 2022 | |
| EPIX ESSA Pharma | Maintains: Overweight | $50 → $20 | $5.12 | +290.63% | 1 | May 12, 2022 | |
| CNTB Connect Biopharma Holdings | Downgrades: Neutral | $25 → $1.5 | $1.44 | +4.17% | 1 | May 5, 2022 | |
| SNSE Sensei Biotherapeutics | Maintains: Overweight | $12 → $10 | $0.60 | +1,580.67% | 2 | Mar 10, 2022 | |
| FIGS FIGS, Inc. | Initiates: Overweight | n/a | $5.63 | - | 1 | Jun 21, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $5.39 | - | 1 | Mar 25, 2021 | |
| XBIT XBiotech | Maintains: Overweight | n/a | $5.55 | - | 2 | Apr 7, 2020 |
Ocular Therapeutix
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $6.66
Upside: +125.23%
Biomea Fusion
Jun 7, 2024
Maintains: Overweight
Price Target: $45 → $10
Current: $4.42
Upside: +126.24%
Halozyme Therapeutics
Jun 7, 2024
Downgrades: Neutral
Price Target: $48 → $51
Current: $52.02
Upside: -1.96%
Nurix Therapeutics
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $20.91
Upside: +67.38%
CytomX Therapeutics
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $1.33
Upside: +163.16%
Context Therapeutics
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.81
Upside: +148.62%
ImmunityBio
Apr 29, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.27
Upside: -4.31%
Acrivon Therapeutics
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $5.86
Upside: +411.95%
Boundless Bio
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $4.19
Upside: +377.33%
Achilles Therapeutics
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.80
Upside: +149.38%
Keros Therapeutics
Mar 27, 2024
Maintains: Overweight
Price Target: $105
Current: $43.77
Upside: +139.89%
LENZ Therapeutics
Mar 27, 2024
Initiates: Overweight
Price Target: $28
Current: $17.69
Upside: +58.28%
Day One Biopharmaceuticals
Mar 26, 2024
Maintains: Overweight
Price Target: $40
Current: $13.58
Upside: +194.55%
I-Mab
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $1.62
Upside: +517.28%
Iovance Biotherapeutics
Mar 14, 2024
Maintains: Overweight
Price Target: $18 → $19
Current: $8.06
Upside: +135.73%
Revolution Medicines
Mar 11, 2024
Initiates: Overweight
Price Target: $43
Current: $38.81
Upside: +10.80%
Cardiff Oncology
Mar 1, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $2.05
Upside: +241.46%
Schrödinger
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $18.76
Upside: +166.52%
Tango Therapeutics
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $9.00
Upside: +100.00%
Aadi Bioscience
Dec 15, 2023
Maintains: Overweight
Price Target: $30 → $5
Current: $1.42
Upside: +252.11%
Repare Therapeutics
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $3.33
Upside: +650.75%
Turnstone Biologics
Aug 15, 2023
Initiates: Overweight
Price Target: $20
Current: $2.65
Upside: +654.72%
Gilead Sciences
Jul 24, 2023
Maintains: Overweight
Price Target: $105 → $100
Current: $68.64
Upside: +45.69%
Black Diamond Therapeutics
Jul 14, 2023
Initiates: Overweight
Price Target: $11
Current: $4.70
Upside: +134.04%
Exelixis
May 10, 2023
Assumes: Overweight
Price Target: $28
Current: $22.25
Upside: +25.84%
Catalyst Pharmaceuticals
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $15.77
Upside: +26.82%
ESSA Pharma
May 12, 2022
Maintains: Overweight
Price Target: $50 → $20
Current: $5.12
Upside: +290.63%
Connect Biopharma Holdings
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.44
Upside: +4.17%
Sensei Biotherapeutics
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.60
Upside: +1,580.67%
FIGS, Inc.
Jun 21, 2021
Initiates: Overweight
Price Target: n/a
Current: $5.63
Upside: -
Marker Therapeutics
Mar 25, 2021
Initiates: Overweight
Price Target: n/a
Current: $5.39
Upside: -
XBiotech
Apr 7, 2020
Maintains: Overweight
Price Target: n/a
Current: $5.55
Upside: -